4-AP (Fampridine-SR) passes FDA heart test

A board to discuss future MS therapies in early stage (Phase I or II) trials.

4-AP (Fampridine-SR) passes FDA heart test

Postby rainer » Mon Jan 28, 2008 5:38 pm

<shortened url>

Acorda Therapeutics (nasdaq: ACOR - news - people ) said its multiple sclerosis drug Fampridine-SR does not raise the risk of heart-related side effects anymore than a placebo in a so-called QT cardiac safety study required by the U.S. Food and Drug Administration. Acorda shares were up 20.1%, or $4.38, at $26.16, in afternoon trading.
User avatar
Family Elder
Posts: 367
Joined: Thu Jan 17, 2008 4:00 pm


Return to Drug Pipeline


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service